Please login to the form below

Not currently logged in
Email:
Password:

regorafenib

This page shows the latest regorafenib news and features for those working in and with pharma, biotech and healthcare.

NICE backs Pfizer’s Xeljanz for RA

NICE backs Pfizer’s Xeljanz for RA

Meanwhile, NICE has decided to remove Bayer ’s gastrointestinal stomach tumour (GIST) treatment Stivarga (regorafenib) from the cancer drugs fund (CDF) to make it routinely available to some patients on the

Latest news

  • Bayer's Nexavar backed by NICE for liver cancer Bayer's Nexavar backed by NICE for liver cancer

    Amanda Cunnington, head of patient access at Bayer UK, said the company recently submitted its new HCC drug Stivarga (regorafenib) for review by NICE and the Scottish Medicines Consortium (SMC) "with

  • EMA clears Bayer's Stivarga for liver cancer EMA clears Bayer's Stivarga for liver cancer

    The European Medicines Agency (EMA) approved oral multikinase inhibitor Stivarga (regorafenib) for patients with HCC who have been treated first-line with Bayer's older drug Nexavar (sorafenib), matching the

  • FDA OK for Stivarga ends decade-long drought in liver cancer FDA OK for Stivarga ends decade-long drought in liver cancer

    Oral multikinase inhibitor Stivarga (regorafenib) has been cleared by the US regulator for patients with hepatocellular carcinoma (HCC) who have been previously treated with Bayer's older drug Nexavar (sorafenib).

  • Bayer nets speedy US review for regorafenib in liver cancer Bayer nets speedy US review for regorafenib in liver cancer

    Bayer nets speedy US review for regorafenib in liver cancer. Priority review in HCC boosts hopes for rejuvenation of Stivarga to combat declining sales. ... Regorafenib - sold as Stivarga for colorectal and gastrointestinal stromal (GIST) tumours - has

  • Xarelto leads the charge at Bayer Xarelto leads the charge at Bayer

    Colorectal cancer and gastrointestinal stromal rumour (GIST) therapy Stivarga (regorafenib) disappointed however, with sales down 25% thanks to increased competition in the US, although Bayer is hoping to reinvigorate the product ... Initial results from

More from news
Approximately 8 fully matching, plus 35 partially matching documents found.

Latest Intelligence

  • Pharma deals during August 2013 Pharma deals during August 2013

    To add to the glitter are two marketed drugs partnered with Bayer: Nexavar (sorafenib) for the treatment of advanced kidney and liver cancer and Stivarga (regorafenib) for the treatment of metastatic

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics